SOURCE: Spotlight Innovation Inc.

Spotlight Innovation Inc.

February 04, 2016 08:30 ET

Spotlight Innovation Inc. Updates Its Company Overview for Prospective Buyers of Its Shares, Investors and Current Shareholders

WEST DES MOINES, IA--(Marketwired - Feb 4, 2016) - Spotlight Innovation Inc. (OTCQB: STLT) on February 3, 2016, filed a Form 8-K containing a Company Overview presentation it plans to present to prospective buyers of its shares, investors and current shareholders. The Company Overview presentation can be found on the Company's website at

Cris Grunewald, President and Chief Executive Officer of Spotlight Innovation, said, "We have made continued and meaningful advances over the past few months and believe that now is an appropriate time to increase our visibility with the investment community. We are most pleased with the progress we have made with our cancer and infectious disease platform biotechnologies, and we encourage investors and shareholders to review our updated investor presentation."

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative and proprietary platform technology candidates with a focus on cancer drugs and related treatment therapies, solutions for infectious disease, and other specialty and unique opportunities. Access to platform technology candidates is accomplished via our extensive relationships with many leading academic institutions and other sources. We provide value-added development capability and funding in order to accelerate development progress. When commercially significant benchmarks have been achieved, we will partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit or follow us on

Forward Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding the Company's efforts to develop and commercialize its various technologies. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technologies, the inability to hire appropriate staff to develop the technologies, unforeseen technical difficulties in developing the technologies, the inability to obtain regulatory approval for human use, competitors' therapies proving to be more effective, cheaper or otherwise more preferable, the inability to market a product, all of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information